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Abstract
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of lymphocyte
homeostasis and immunological tolerance due primarily to genetic defects in Fas (CD95/APO-1;
TNFRSF6), a cell surface receptor that regulates apoptosis and its signaling apparatus.
Methods: Fas ligand gene mutations from ALPS patients were identified through cDNA and
genomic DNA sequencing. Molecular and biochemical assessment of these mutant Fas ligand
proteins were carried out by expressing the mutant FasL cDNA in mammalian cells and analysis its
effects on Fas-mediated programmed cell death.
Results: We found an ALPS patient that harbored a heterozygous A530G mutation in the FasL
gene that replaced Arg with Gly at position 156 in the protein's extracellular Fas-binding region.
This produced a dominant-interfering FasL protein that bound to the wild-type FasL protein and
prevented it from effectively inducing apoptosis.
Conclusion: Our data explain how a naturally occurring heterozygous human FasL mutation can
dominantly interfere with normal FasL apoptotic function and lead to an ALPS phenotype,
designated Type Ib.
Background
ALPS is a heritable disorder of lymphocyte homeostasis
due to defects in apoptosis typically involving mutations
in genes mediating the Fas/CD95/APO-1 pathway of pro-
grammed cell death. Patients with ALPS have chronic,
nonmalignant lymphadenopathy and splenomegaly of
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mas, autoimmune complications, especially autoimmune
cytopenias, increased numbers of normally rare α/βTCR
CD3+CD4-CD8- or "double negative T cells" (DNTs), and
defective lymphocyte apoptosis in vitro [1]. Most ALPS
patients have genetic abnormalities in the Fas pathway.
Fas is a cell surface receptor in the tumor necrosis factor
receptor suuper-family and upon stimulation it activates a
caspase-mediated apoptosis pathway that controls the
homeostasis of mature lymphocytes. ALPS is subdivided
into: 1.) Type Ia, ALPS with mutant Fas; 2.) Type Ia, ALPS
with somatic mutant Fas in the normally rare population
of DNTs; 3.) Type Ib, ALPS with mutant Fas ligand; 4.)
Type II, ALPS with mutant caspases; 5.) Type III, ALPS
without any defined genetic cause yet. 6.) Type IV, ALPS
patients with mutant N-Ras [2]. Majority of ALPS patients
are Type Ia and have heterozygous mutations of Fas gene
(TNFRSF6, tumor necrosis factor receptor gene super-fam-
ily member. Interestingly, a somatic N-Ras mutation in
hemopoietic cells has been found to cause ALPS like syn-
drome [2]. Homozygous mutations in Fas in both mice
and humans are associated with a more severe phenotype
than is seen with heterozygous mutations [3-5]. In partic-
ular, MRL/lpr-/- mice that are homozygous for Fas muta-
tions develop an ALPS-like disease.
The human gene encoding the ligand for Fas (FasL;
TNFSF6) is located on chromosome 1q23 and spans
about 8 kb, including 4 exons that are translated into a
281 amino acid, or approximately 40 kD type II mem-
brane protein. The human and mouse FasL proteins have
77% amino acid identity [6]. Since mice homozygous at
the gld (generalized lymphoproliferative disease) allele of
TNFSF6 develop an ALPS-like phenotype [7], FasL defects
in humans were predicted to have a similar clinical phe-
notype.
As in mice, dysfunctional molecules other than Fas that
participate in the same signaling pathway, can produce
ALPS in humans. Recently, some cases of ALPS, termed
Type II and ALPS-like disease have been shown to be due
to mutations in caspases 10 and 8, respectively; these are
downstream signaling molecules in the Fas pathway [8-
13].
The great majority of Fas mutations result in dominant-
negative inhibition of apoptosis, due to the random
assembly of mutant and normal Fas protein chains at the
ligand-independent preassociation stage of Fas trimer for-
mation [14,35]. Penetrance is higher in families with
mutations that severely disrupt the Fas death domain
[15]. There is striking variability in the degree of severity
to which family members bearing the same Fas defective
allele express features of ALPS, a variability that is likely
explained by modifier genes. For example, our recent
studies associate the presence of HLA B44 as protective for
clinical ALPS [16]. An additional association study
showed caspase-10 polymorphisms might be protective
factors in ALPS Type Ia patients [9]. Similar variability is
also noted when the murine null allele for Fas, lpr, is bred
into different strains of mice [17]. The lymphoprolifera-
tive features of human ALPS appear to diminish in adult-
hood [1].
Given that mice harboring homozygous FasL mutations
develop chronic lymphadenopathy and autoimmune dis-
ease, this led us to look for and ultimately identify an
ALPS Type Ib patient, among others, as part of an
extended study of patients with features of ALPS to char-
acterize the disorder, its complications, management and
causes. One case of a patient with systemic lupus ery-
thematosus (SLE) in an adult has been reported in associ-
ation with a heterozygous 84 bp in-frame deletion in
TNFSF6 [18]. That individual was a 64-year-old African-
American male with generalized adenopathy but not
splenomegaly, malar rash, arthritis, serositis, renal dis-
ease, leukopenia, and laboratory features of SLE including
positive anti-nuclear and anti-DNA antibodies. Thus, he
did not appear typical of ALPS, nor did he meet all ALPS
case criteria based on available information. More
recently an adult patient with a homozygous allele encod-
ing a FasL protein with a deleterious amino acid substitu-
tion in the intracellular portion has been described [19].
She exhibited defective apoptosis and other hallmarks of
ALPS. The molecular mechanism underlying the immun-
opathology appeared to be the absence of any normally
functional FasL protein. A number of studies have also
reported FasL gene polymorphisms associated with
autoimmune conditions such as systemic lupus erythema-
tosus in specific human populations, but others have
failed to find such associations in patients with Hashim-
oto's thyroiditis, Graves' disease, Type I diabetes mellitus,
and Sjogren's syndrome [20-25].
In this report we describe a new case of ALPS Type Ib due
to a gene mutation that causes a functional alteration of
the FasL protein. We found that the mutant protein asso-
ciates with wild-type FasL and by so doing, dominantly
interferes with apoptosis induction. These data strengthen
the dominant interference model by which heterozygous
FasL gene mutations are capable of causing disease due to
impaired apoptosis.
Methods
Patient studies
Over a period of 13 years, more than 700 subjects includ-
ing patients with clinical and laboratory features of ALPS
and their relatives have been evaluated by our group at the
National Institutes of Health. All subjects were enrolled in
institutional review board approved research protocolsPage 2 of 14
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subjects, 240 cases of ALPS were identified: 148 patients
(62% of ALPS cases) among 81 families had Fas germline
mutations; 4 patients (2%) were positive for somatic
mutant Fas in the rare population of DNTs; 2 patients (<
1%), one of whom fulfilled ALPS criteria, had mutant Fas
ligand; 7 patients (3%) were positive for mutant caspases;
1 patient (< 1%) was positive for a somatic N-Ras muta-
tion; and the associated apoptosis mutation has yet to be
identified in 79 patients (33%) among 76 families.
Isolation of peripheral blood lymphocytes (PBLs)
Peripheral blood was collected in anticoagulant, and PBLs
were isolated by Ficoll-Hypaque density gradient centrifu-
gation. The isolated PBLs were cultured in RPMI 1640
supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 μg/ml streptomycin and 100 U/ml peni-
cillin (complete medium) at 37°C in a humidified atmos-
phere with 5% CO2. T cell-enriched populations from
PBLs were obtained by stimulation with phytohemagglu-
tinin (PHA, 5 μg/ml, Pharmacia Biotech) in the media for
two days and culturing in complete medium for two days
followed by culture in medium containing IL-2 (100 U/
ml) for a minimum of an additional 2 days until they were
used.
Fas Ab-induced apoptosis
On the day preceding the apoptosis determination exper-
iment, the T cells were fed with fresh IL-2-containing
medium. For each sample, 100 μl of cells were plated in
triplicate in 96-well plates at a density of 2 × 106 cells per
well. Apoptosis was induced by the addition of 100 μl
media containing 1 μg/ml anti-Fas antibody (APO-1-3,
Kamiya Biomedical) with 1 μg/ml protein A (Sigma). No
antibody was added to control wells. The cells were incu-
bated at 37°C for 24 hours and then assayed for quantifi-
cation of apoptosis, as reported previously [26]. Briefly,
cells were harvested on ice and propidium iodide (final
concentration 3.3 μg/ml) was added. Fixed time flow
cytometry was performed for 15 minutes to count live
cells using a FACScan flow cytometer (Becton-Dickinson).
Apoptosis was calculated as:
% cell death = (1 - live cells after antibody treatment/live
cells in control tubes) × 100.
Genomic sequence analysis
Genomic DNA was prepared from activated lymphocytes
using standard methods [27]. All four FasL exons and
intron/exon boundaries were amplified from genomic
DNA with the following PCR primers: Exon 1 fwd 5'-TTG
CCT CCT CTT GAG CAG TCA -3'; Exon 1 rev 5'-CAC TTT
GCA AGC CAG GCA GT-3'; Exon 2 fwd 5'-GCA GAA CTT
CTG AGG TAT TTG GAT TC-3'; Exon 2 rev 5'-CAT TAA
CAT AGT TCT GTG CTG AGG ATC-3'; Exon 3 fwd 5'-TAT
GTT AGA CTG TTG CCA TTT ACG G-3'; Exon 3 rev 5'-AAG
CTT TCC CAA ATC TCA CCT GTA-3'; Exon 4 fwd 5'-AGC
TGT CAT TCT GGG TGA AAC ATT-3'; Exon 4 rev 5'-GAC
ATT TTG AAC CCT GTG GTC TC-3'. PCR was performed
with "Ready To Go" PCR beads (Amersham Pharmacia) as
instructed by the manufacturer. After heating for five min-
utes at 95°C, 30 reaction cycles consisting of 30 sec at
95°C, 30 sec at 60°C and 30 sec at 72°C were performed
in a 9700 GeneAmp PCR System (PE Applied Biosystem).
The PCR products were loaded on an agarose gel, and the
amplicons were excised and purified using purification
kits (QIAGEN). The sequences were analyzed with the
same primers used for PCR with a dRhodamine Termina-
tor cycle sequencing kit on an ABI 377 DNA sequencer (PE
Applied Biosystems). Sequence analyses of the genes
encoding Fas and caspase-10 were performed according to
methods described in Fisher et al [4] and Wang et al [8].
Construction of tag-labeled FasL expression vectors (wild 
type, Pt 86, Pt 55C, and hgld)
Complete cDNA of the wild-type human FasL in pBlue-
Script [6] was used as a template in PCR and cloning reac-
tions. Constructs were generated to express FasL with
FLAG or HA tags by inserting 9 amino acids after the cleav-
age site between amino acids 138 and 139. Five PCR prim-
ers were used to amplify the complete FasL cDNA with the
tags as two separate fragments. Fragment Ia for FLAG tag
was generated by using primer 1 (5'-GGA ATT CCT CAC
CAG CTG CCA TGC AGC-3') and primer 2 (5'-TCC CCG
CGG CTT GTC ATC GTC GTC CTT GTA GTC GAT ATC
GTG GCC TAT TTG CTT CTC C-3'). Fragment Ib for an HA
tag was generated by using primer 1 paired with primer 3
(5'-TCC CCG CGG AGC GTA GTC TGG GAC GTC GTA
TGG GTA GAT ATC GTG GCC TAT TTG CTT CTC C-3').
Fragment II was generated by using primer 4 (5'-TCC CCG
CGG CCC AGT CCA CCC CCT GAA A-3') paired with
Primer 5 (5'-GCT CTA GAT TAG AGC TTA TAT AAG CCG-
3'). Fragment Ia or Ib was digested with EcoRI/SacII and
fragment II was digested with SacII/XbaI. Then fragment
Ia or Ib was ligated with fragment II and inserted into the
EcoRI/XbaI sites of the pCI-neo expression vector
(Promega). The FasL mutations identified in Pt 86 and Pt
55C and the corresponding mouse gld mutation were
introduced into the FLAG-tagged normal human FasL
expression (the gld change introduced into the human
gene is called hgld) construct by site-directed mutagenesis
(Stratagene). All of the constructs were verified by
sequencing.
Expression of wild-type or mutant FasL in transfected cells
Human embryonic kidney tumor 293T cells (5 × 105) cul-
tured in DMEM containing 10% FCS and antibiotics were
plated onto a 6 well plate and incubated overnight. The
cells were then transfected with 0.2~1 μg of plasmid DNA
expressing wild type or mutant FasL using the Fugene™ 6-Page 3 of 14
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mutant FasL molecules could associate physically with
wild type (WT) FasL, the HA-tagged WT-FasL and the
FLAG-tagged Mut-FasL constructs were co-transfected into
293T cells. The transfection efficiency was above 50% for
Jurkat cells and more than 70% for 293T cells as assessed
through surface staining of live cells or immunohisto-
chemical staining of fixed cells by FITC conjugated anti-
FLAG antibody (Sigma).
Immunoprecipitation and Western blot analysis
The 293T cells transfected with various FasL expressing
constructs were lysed in 400 μl lysis buffer (50 mM
HEPES, pH 7.6; 150 mM NaCl; 1 mM EDTA; 1% NP-40;
1 × protease inhibitor cocktail tablets from Boehringer).
For immunoprecipitation of epitope-tagged FasL protein,
the cell lysates were incubated with 10 μg/ml mouse-anti-
HA antibody (Covance), on ice for 30 minutes. Then, a 20
μl slurry of Protein A Sepharose beads (Pharmacia) was
added to each tube and rotated the samples at 4°C for 2
hours. After four washes with the lysis buffer, the beads
were resuspended in 30 μl of SDS loading buffer with 0.2
M DTT. The samples were boiled for 5 minutes and the
proteins were separated by SDS electrophoresis and trans-
ferred to nitrocellulose membranes. These blots were
treated with a mouse anti-FLAG antibody (Sigma) fol-
lowed by an HRP-conjugated secondary antibody. The
proteins were detected using the Super signal system
(Pierce Chemical Co.).
FasL-mediated cytotoxicity assay
Fas expressing Jurkat cells cultured in complete RPMI
1640 medium were labeled with PKH2 dye using a PKH2-
GL Fluorescent Cell Linker Kit (Sigma). As monitored by
flow cytometry, the labeling efficiency was higher than
99%. Aliquots of 0.3 ml of 5 × 105/ml labeled Jurkat cells
were dispensed into 24-well plates to serve as target cells.
The 293T cells transfected with FasL the day before were
harvested and added as effector cells in ratio to target cells
of 1:1 or 3:1. To detect dominant interference, 293T cells
transfected with 0.2 μg to 0.4 μg of wild type or mutant
FasL-expressing plasmid DNAs were used as effector cells
at a ratio to target cells of 2:1. The 293T cells transfected
with a pCI-neo expression vector with no insert were used
as control effector cells. For the cytotoxicity assay involv-
ing PBLs from Pt 86 and his father who harbored the same
Fas ligand gene mutation, the PBLs were cultured in RPMI
medium containing 5 μg/ml PHA-P (Sigma) for 48 hours
and used as effector cells. The mixtures of effector and tar-
get cells were incubated at 37°C for 3 hours. Then they
were harvested, washed once with PBS and analyzed by
flow cytometry. A gate was set to enumerate the labeled,
live Jurkat cells. The percentage of cell death was calcu-
lated as mentioned above in the apoptosis assay.
Plasma cytokine levels
Cytokine levels were measured in samples of plasma from
the Pt. 86, his extended immediate nuclear family mem-
bers, also in Pt 55C and healthy controls using highly sen-
sitive commercial EIAs kit (R&D Systems) according to the
manufacturer's instructions.
Results
Clinical histories
Patient 86 (Pt 86) in the NIH ALPS series is a 20-year-old
white male with moderate generalized lymphadenopathy
and splenomegaly since 18 months of age. He developed
thrombocytopenia, neutropenia and anemia at age three,
which recurred despite repeated courses of steroids and
intravenous immunoglobulin, eventually necessitating
splenectomy at age eight. At age ten he developed mas-
sively enlarged axillary lymph nodes that were excised.
Histological analyses of spleen and lymph node sections
revealed a reactive process with numerous follicles and T
cell regions that were markedly expanded by infiltrating T
cells and non-caseating granulomas. Although mycobac-
terial infection was suspected, all stains and cultures and
TB skin tests were negative and no antimicrobial drugs
were dispensed. At age 11 following a respiratory infec-
tion he developed granulomatous interstitial pneumoni-
tis that improved spontaneously over several months with
no treatment. Elevated liver function tests two- to three-
fold above normal were first detected at age 15 years. A
liver biopsy showed non-necrotizing granulomatous hep-
atitis and marked lobular inflammation without fibrosis.
His elevated liver function tests have remained stable over
time, and a repeat liver biopsy is planned. At age 20 years,
he had the onset of what has become chronic recurrent
sinusitis that responds to standard antibiotic treatment.
His history is remarkable for three episodes of herpes
zoster without sequelae at ages 9.6, 12.5 and 15 years. At
the time of study he was well, except for continued mod-
erate generalized lymphadenopathy, residual interstitial
lung densities and autoimmune hepatitis. He has been
followed at the NIH for over 5 years. He has had a history
of serum immunoglobulin levels that have been low or
borderline low (Table 1), but he has had no serious infec-
tions.
The patient's father had lymphadenopathy as an adoles-
cent and underwent a bone marrow biopsy and other
studies that excluded lymphoma. The records of that
assessment and tissue samples are unavailable. He has
been healthy otherwise except for psoriatic arthritis. The
paternal grandparents recall no histories of family mem-
bers suggestive of ALPS.
An unrelated patient (Pt 55C), is a 13-year-old white
female diagnosed with thrombocytopenia with positive
anti-platelet antibodies at age 3 years during hospitaliza-Page 4 of 14
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idiopathic thrombocytopenic purpura treated with intra-
venous immunoglobulin, but no history of hepat-
osplenomegaly or chronic adenopathy. Although this
patient does not manifest typical ALPS, coincidentally,
she has a cousin with ALPS Type Ia. As an immediate
patient family member, she is included in our genetic
screening.
Abnormal lymphocyte phenotype in Pt 86
Surface phenotypes of circulating lymphocytes of Pt 86
and members of his family are summarized in Table 2.
The patient had a moderate absolute B-cell and T-cell lym-
phocytosis with increased numbers and percentage of
CD4-CD8-CD3+ (DN) T cells. Notably, most of these were
γδ T cells rather than αβTCR+ DNT cells that are character-
istic of ALPS [1]. In other Type Ia ALPS patient, accumula-
tion of γδTCR+ DNT has also been reported [28].
Furthermore, CD4+ T cells were elevated which is also not
usually the case in ALPS Type Ia. However, we found an
increase in HLA-DR+ T cells and a decreased (less than 1)
ratio of CD3+/CD25+ to CD3+/DR+ ratio, which are typical
of patients with ALPS [29]. The patient's parents and two
siblings showed essentially normal phenotypes, but there
were slightly increased B cells in the father and marginal
increases in γδ T cells in both unaffected sisters. Similar to
the findings in Pt 86, Pt 55C's lymphocyte phenotype also
showed a moderate generalized T and B lymphocytosis,
with increased numbers of αβ(39, Nl < 18/uL) and γδ
(370, Nl < 60/uL) TCR+ CD3+CD4-CD8-T cells,.
Cytokine profile in Pt 86
ALPS Type Ia is associated typically with significant eleva-
tions of serum and lymphocyte IL-10, and relatively low
or normal levels of Th1 cytokines [30]. To help determine
whether Pt 86, his family members, or Pt 55C had these
features of ALPS, their sera were analyzed with sensitive
immunoassays during the years of our clinical follow up
examination. The median level of IL-10 in normal indi-
viduals in our laboratory is 3.4 pg/ml [30]. We observed
moderately elevated levels of IL-10 in Pt 86 (mean = 20
pg/ml, 14~27 pg/ml over 5 years), in his father (mean =
9.5 pg/ml, 5~14 pg/ml over 2 years), but levels were nor-
mal in Pt 86's extended-nuclear family including the FasL-
mutant carrier grandmother, as well as in Pt 55C. Circulat-
ing IL-2 level in Pt 86 was slightly elevated (mean = 28 pg/
ml, 11~79 pg/ml over 5 years), 0~11 pg/ml (during 2
years) in his father, and undetectable in his mother, and
41 pg/ml in Pt 55C (in the range in unaffected ALPS fam-
ily members). In summary, Pt 86 shows a cytokine profile
that is less clearly oriented towards a Th2 response than
that is typical in ALPS Type Ia patients [31].
Identification of FasL mutations
Given the generally typical history, clinical features, and
immunophenotype in Pt 86, the diagnosis of ALPS was
expected. Yet, DNA sequencing revealed no mutations in
the genes encoding Fas or caspase-10, which have been
previously identified to cause ALPS [3,4,8]. We therefore,
sought mutations in other apoptosis genes in these indi-
viduals and in 38 others in whom a genetic basis for ALPS
had not been defined. The only mutations found in
TNFSF6 to date were in these two subjects. Pt 86, his
father and paternal grandmother share a heterozygous
FasL A530G mutation (Figure 1a,b) that leads to substitu-
tion of arginine to glycine at peptide 156 (R156G). The
mutation was not observed in the patient's healthy
mother and two sisters (Figure 1b). The arginine residue
in FasL is conserved among mouse, rat, pig, monkey, and
humans (Figure 1c) suggesting that it may be important
for FasL function.
Pt 55C had no Fas or caspase-10 abnormalities, but car-
ried a heterozygous A320G base change (Figure 1a) that
causes a methionine to valine substitution at amino acid
86 (M86V) in the FasL transmembrane domain (Figure
1c) [6]. This residue is normally a valine in the mouse and
an isoleucine in the rat, suggesting that any hydrophobic,
or weakly polar residue is acceptable. Thus, we hypothe-
size that the change in Pt 55C is not relevant to FasL func-
tion. Neither of the base changes found in Pt 86 or Pt 55C
was observed in the FasL sequences of 100 chromosomes
from 50 normal individuals.
We chose to compare these human sequence alterations
to the gld mouse that carries a homozygous mutation
replacing phenylalanine with leucine at position 273
(equivalent to F275L in human FasL), which is located 7
Table 1: Serum immunoglobulin levels of patient 86
Age 5 Age 11 Age 20
Igs Pt86 Norm. Range Pt86 Norm. Range Pt86 Norm. Range
IgM 30* 99** 43~196 32 121 52~242 210 156 56~352
IgA < 7 68 25~154 56 113 45~236 < 10 171 70~312
IgG 450 780 463~1236 544 1007 608~1572 210 994 639~1349
* All values are in mg/dL.
** The normal values are means within 95% confidence limits.Page 5 of 14
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is absolutely conserved within a region of FasL that is
highly homologous among at least 5 species (Figure 1c)
and is critical for binding of FasL to its Fas receptor [32].
Molecular modeling of the FasL mutations
To help understand the biological implications of the
mutations found in Pt 86 and Pt 55C, we compared
human FasL sequences with those of other species, as well
as the gld mice. Alignment of FasL amino acid sequences
showed 74% homology among human, mouse, and rat
[6]. We also positioned R156 on the molecular model of
soluble rat FasL fragment trimer and a Fas/FasL interac-
tion model based on the 3-dimensional X-ray crystallo-
graphic structure of tumor necrosis factor alpha (TNF-α)
[33,34]. We found that the Pt 86 substitution is located in
a surface-exposed area in the extracellular domain near
the predicted Fas/FasL interface (labeled red in Figure 2a).
The mouse gld substitution at the homologous site in
human FasL (hgld, Phe275Leu; labeled in blue in Figure
2) is predicted by molecular modeling to lie on another
loop of the protein in proximity to the FasL trimer inter-
face. This model predicts that the mutation in Pt 86 may
directly affect Fas-FasL interactions and impair apoptotic
signaling. The heterozygous A320G mutation in Pt 55C,
however, leads to a conservative substitution of Met to Val
at amino acid 86 in the predicted transmembrane domain
(TMD), a region not included in this molecular model.
Given the location, the conservative nature of the muta-
tion in Pt 55C, and the fact that valine normally occupies
this position in mice, this mutation should have no
impact on apoptosis.
Fas-mediated apoptosis is normal in patients with FasL 
mutations
Activated PBLs from Pt 86 and his nuclear family, and
from Pt 55C, were cultured in the presence of IL-2 and
stimulated to undergo apoptosis with an agonistic anti-
Fas antibody. The level of T cell loss for Pt 86 and his rel-
atives were similar to the normal subject (Figure 3). As a
control, defective apoptosis was clearly observed using
lymphocytes from an ALPS Type Ia patient. Pt 55C PBLs
also showed no defect in Fas-induced killing (not shown).
Normal Fas-mediated apoptosis induced by direct recep-
tor stimulation would be expected to be unaffected in per-
sons harboring FasL mutations but normal Fas. Thus,
there were no apparent apoptotic defects in downstream
Fas signaling. It was then critical to directly analyze the
ability of FasL from these individuals to trigger apoptosis.
Impaired cytotoxicity of mutant FasL from Pt 86
FasL-mediated apoptosis was evaluated by determining
the ability of effector cells transfected with various FasL
expression vectors to kill Fas-bearing Jurkat cells. FLAG-
tagged FasL expression constructs were transfected into
293T cells and tested as effectors. As shown in Figure 4a,
at effector to target cell ratios of 1:1 or 3:1, the construct
expressing Pt 86 mutant FasL was substantially less effec-
tive at killing Jurkat cells as compared with the wild type.
By contrast, the Pt 55C construct induced normal levels of
Table 2: Lymphocyte subpopulations in members of family 86
Percent of lymphoid cells (absolute numbers/mm3)
Pt Sib1 Sib2 Mother Father Controls**
Total T Cells
CD3 64.7(2750) 78.6(1336) 80.3(1767) 71.1(1138) 65.1(1172) (832–2028)
CD5 62.8(2669) 79.3(1348) 81.8(1800) 72.4(1158) 68.8(1238) (828–1994)
CD3/ab 51.8(2202) 47.1(801) 75.4(1659) 69.9(1118) 64(1152) (620–2010)
CD3/gd 12(510) 5.3(90) 5.3(117) 0.9(14) 0.9 (16) (9–166)
T Cell Subsets
CD4 36.1(1534) 43.3(736) 52(1144) 41.9(670) 40.6(731) (480–1339)
CD8 26.7(1135) 31.8(541) 31.6(695) 33.5(536) 29.6(533) (351–911)
CD3+CD4-CD8- 9.7(412) 4.6(78) 4.9(108) 1.1(18) 1.3(23) (9–122)
DNT/ab* 1.1(47) 0.8(14) 1.1(24) 0.5(8) 0.5(9) (2–18)
DNT/gd 7.9(336) 3.9(66) 3.4(75) 0.6(10) 0.7(13) (5–59)
T Cell 
Activation
CD4+/HLA-DR+ 14.2(604) 1.6(27) 2.3(51) 2.8(45) 2.7(49) (< = 95)
CD4+/CD25+ 5.2(221) 16.1(274) 11(242) 19.7(315) 22.1(398)
Total B cells
CD20 18.9(803) 8.8(150) 8.1(178) 5.9(94) 19.6(353) (88–330)
*DNT: Double-negative CD4- CD8- T cells, either TCRαβ+ or TCRγδ+
** 95% confidence intervals for adult normals.Page 6 of 14
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Fas ligand mutations in the Pt 86, Pt 55C and the gld mouseigure 1
Fas ligand mutations in the Pt 86, Pt 55C and the gld mouse. Sequencing of genomic DNA shows a heterozygous A530G muta-
tion in Pt 86 and a A320G mutation in Pt55C depicted in panel (a) for double peaks of A and G from normal and mutant alleles 
amplified from genomic DNA. The family pedigree in panel (b) reveals the same mutation was found in his father, and paternal 
grandmother (labeled with m) but not in his healthy mother or two sisters. Black, the affected individual; gray, individuals with 
the mutation but not the full picture of ALPS. This mutation leads to an amino acid change of A156G, the heterozygous A320G 
mutation found in Pt 55C FasL genomic DNA leads to an amino acid change M86V in the transmembrane domain (TMD), and 
the gld mutation in mouse is shown at amino acid site 275, all compared to the wild type sequences at these sites in 5 species, 
as aligned in panel c.
BMC Medical Genetics 2007, 8:41 http://www.biomedcentral.com/1471-2350/8/41apoptosis. The human FasL bearing the murine gld muta-
tion (hgld) exhibited essentially no cytotoxic activity. The
transfection efficiency and protein expression from all 4
FasL constructs were similar by Western blot analysis and
immunohistochemical staining of fixed cell lysates (data
not shown).
Interestingly, FasL surface expression by flow cytometry
using the hgld construct was substantially less than the
other three constructs (Figure 4c). Thus, the lack of killing
of Jurkat cells by the hgld FasL construct may due, at least
in part, to low levels of FasL expression on the cell surface.
Dominant interference of the mutant FasL from Pt 86
Previous studies indicated that most Type Ia ALPS patients
carry heterozygous Fas mutations, and that the mutated
Fas molecules have dominant interfering effects on the
ability of normal Fas molecules to initiate apoptosis [4].
(a) Molecular modeling of the extracellular, soluble portion of rat FasLFigure 2
(a) Molecular modeling of the extracellular, soluble portion of rat FasL. The soluble rat FasL trimer fragment was visualized 
based on the structure of TNF-α [33]. The Pt 86 FasL mutation is labeled in red and the hgld mutation is labeled in blue in side 
(left) and front (right) projections. The Pt 55C FasL mutation is not indicated in this model since it is located in the transmem-
brane domain, which is outside of the region in the model depicted. (b) A diagram of cloning strategy for epitope-tagging Fas-
ligand protein.
1 134 280 a.a.
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BMC Medical Genetics 2007, 8:41 http://www.biomedcentral.com/1471-2350/8/41To address the mechanism by which the heterozygous
FasL mutation in Pt 86 leads to defective apoptosis and
ALPS, we examined the possibility that abnormal FasL
interferes dominantly with normal FasL. We then co-
transfected Pt 86 and wild type FasL constructs and
observed that the cytotoxicity was indeed much lower
than that induced by the wild type FasL construct alone
(Figure 4b). In fact, an approximately equimolar mix of
the wild type and mutant plasmids yielded no greater cell
loss than mutant FasL alone (Figure 4b). Constructs
expressing hgld or Pt 55C variants of FasL had no effect on
killing by wild-type FasL (data not shown). Thus, Pt 86
mutant FasL interferes in a dominant fashion with killing
from normal FasL.
PBLs from Pt 86 and his father have diminished cytotoxic 
activity
Having shown that FasL of Pt 86 is impaired in initiating
apoptosis, it was important to show that PBLs taken
directly from this patient are similarly defective in induc-
ing Fas-mediated cell death. We therefore assessed
whether PBLs from Pt 86, his father and normal individu-
als could induce the death of Fas-expressing Jurkat cells.
Cell death was reproducibly reduced for both Pt 86 and
his father, compared to normal cells (Figure 5). It is there-
fore clear that action of the wild-type FasL allele in the
patient and his father is impaired by the presence of the
mutant allele.
Mutant FasL interacts with wild type FasL
Fas mediates lymphocyte apoptosis as a pre-associated
homotrimer [14]. Evidence indicates that FasL spontane-
ously assumes a homotrimeric structure to symmetrically
engage the trimeric Fas assembly [34]. It may, therefore,
be possible to detect the physical association of mutant
and/or wild type FasL proteins into an oligomeric struc-
ture which could explain the dominant inhibition of
apoptosis in people with heterozygous FasL mutations.
We expressed in 293T cells of various forms of FasL with
HA or FLAG tags inserted right after the metalloprotease
cleavage site of FasL protein (Figure 2b). We found that all
three FLAG-tagged FasL mutant proteins associate with
the HA-tagged wild type FasL in immunoprecipitation
experiments (Figure 6). Control western blots on cell
lysates using anti-FLAG antibody showed that the FasL
with mutations in Pt 86, Pt 55C or hgld were expressed
comparably to that of WT FasL (Figure 6b). We observed
no cross-reaction of anti-FLAG and anti-HA antibodies
(data not shown). Thus the Pt 86 and hgld FasL proteins
have rather normal overall conformations and can associ-
ate with WT FasL. The dominant interfering effect we
observe with the Pt 86 heterozygous FasL mutation
implies that the amino acid substitutions corrupt receptor
interaction and apoptotic signaling, but still permit oli-
gomerization of the mutant FasL chain with the wild-type
chain. Hence, the mutant FasL chains prevent normal FasL
chains from functioning and therefore dominantly inter-
fere with apoptosis.
Discussion
Here we report a young adult, Pt 86, with ALPS due to a
point mutation in the TNFSF6 gene encoding FasL. He
meets the defining criteria for ALPS by exhibiting chronic
lymphadenopathy, splenomegaly, autoimmune hepatitis,
elevated numbers of CD4-CD8-TCRαβ+ T cells and an
apoptosis defect. However, unlike most patients with
ALPS, he has no abnormality of the Fas receptor gene
TNFRSF6, or of downstream intracellular signaling mole-
cules that transmit the death signal. Rather, his FasL is
defective. Thus, he can be classified as having a previously
undocumented form of heterozygous ALPS (Type Ib)
reserved by analogy with gld mice for cases arising because
of FasL mutations.
Pt 86 has notable features that are not typical of ALPS
patients with Fas mutations. These include hypogamma-
globulinemia and granulomatous infiltration of the
spleen, lymph nodes and liver. His hypogammaglob-
ulinemia in this setting may be due to an abnormality in
T cell help rather than a primary B cell defect. Paradoxi-
cally both the patient and his father, who carries the same
FasL mutation on one of his alleles, have elevated circulat-
ing B cell numbers. In addition, Pt 86, but not his father,
has a decreased percentage of CD3+CD25+ T cells, known
to represent a regulatory subset, while the percentage of
his CD3+ HLA-DR+ T cells is elevated, consistent with
ongoing activation in vivo. Clinical evidence for Pt 86 in
Fas-mediated T-cell apoptosis in Family 86igur  3
Fas-mediated T-cell apoptosis in Family 86. The percentage 
of T cells killed by the treatment with an agonistic anti-Fas 
antibody is shown for the patient, members of his extended 
family, a normal control, and an ALPS Type Ia patient with a 
mutation in the Fas death domain. Percent cell loss is calcu-
lated as (1-number of cells with antibody stimulation/number 
of cells without stimulation) 100%. One representative of 
three repeated experiments is shown.
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Cytotoxic effects of transfected FasL constructs on Jurkat cellsFigure 4
Cytotoxic effects of transfected FasL constructs on Jurkat cells. Cytotoxicity is reflected by the percentage of Fas-positive Jur-
kat cells killed by co-culture with transfected 293T cells. (a) Ratios of 1:1 or 3:1 were used for 293T cells (effectors) trans-
fected with either of 4 constructs (WT; Pt 86, black; Pt 55C, open; and hgld, shaded) to Jurkat cells (targets). Averages of % cell 
death and error bars are shown as normalized to that of WT FasL-induced death. Data represent at least 3 experiments. (b) 
Cotransfection of the Pt 86 (R156G) mutant FasL with wild type FasL. 293T cells were transfected with a total of 0.4 or 0.2 μg 
of wild-type FasL only (open bars); with Pt 86 mutant mixed with wild-type FasL at ratio of 1:1 (black bars); and with Pt 86 
mutant FasL only (shaded bars). The ratio of effector to target cells was 2:1 in this experiment. Means and error bars of the 
percentage Jurkat cells death are shown. Data represent two independent duplicate experiments. (c) Surface staining of FLAG-
tagged FasL in 293T cells transfected with empty vector, hgld-, WT-, and Pt 86- FasL as indicated.
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BMC Medical Genetics 2007, 8:41 http://www.biomedcentral.com/1471-2350/8/41support of a cellular immune defect is his history of diffi-
culty in controlling multiple viral infections: he has suf-
fered from cutaneous warts and chronic lesions of
molluscum contagiosum; and he had three discrete epi-
sodes of herpes zoster in the absence of immunosuppres-
sive medications. Recent studies suggest that FasL ligation
to Fas on T cells can act as a positive costimulatory signal
in antigen-specific T cell activation [36,37]. Moreover,
direct Fas engagement has also been observed to provide
a costimulatory effect on T cell proliferation [38]. Thus,
ineffectual Fas-FasL interactions might produce a T cell
activation defect in a fashion similar to that seen with
mutations in CD40-ligand (CD154) in X-linked hyper-
IgM syndrome. Interestingly, the adult immunoglobulin
levels for Pt 86 suggest a partial isotype switch defect with
low IgA and IgG and IgM in the upper range of normal.
However, if this were of substantial magnitude, one
should observe T cell activation defects in patients with
heterozygous and homozygous Fas mutations, neverthe-
less, they are substantially milder than those in CD154
deficiency. We have seen instances of herpes zoster infec-
tion and poor antibody responses following immuniza-
tions in ALPS Type Ia patients. However, cellular immune
defects are not characteristic of gld mice indicating that
there is a partial signaling effect or some other reason for
these clinical findings [7].
Pt 86 originally presented with prolonged granulomatous
interstitial pneumonitis that developed after a respiratory
infection, and granulomas were evident on histological
evaluation of his splenic, lymph node and liver tissues.
Interestingly, after some viral infections the FasL-deficient
gld mice also develop inflammatory responses in the pul-
monary interstitium that persist long after the infectious
agent has disappeared [39]. Nonetheless, the cause of the
granulomas in Pt 86 remains unclear. No infectious etiol-
ogy was found and the condition remained stable without
antimicrobial intervention. Although his histology resem-
bled sarcoidosis, Pt 86 lacked the cutaneous, neurological,
and ocular features of that disease. Further patients with
ALPS Type Ib must be studied in order to elucidate the
relationship between FasL defects and granulomas.
Lymph node biopsy of the FasL defective patient
described by Del-Rey et al [19] revealed sinus histiocytosis
but no granulomas. Since their patient had a complete
loss of function while Pt 86 has only partial loss of FasL
function, it is possible that the difference in histology
reflects this qualitatitive difference in function.
Another interesting difference between the patient
reported by Del-Rey et al. [19] and patient 86 lies in the
impressive history of recurrent infections in the former
despite chronically elevated immunoglobulins. In con-
trast, Pt 86 has suffered from relatively few infections
despite his pan-hypogammaglobulinemia. This difference
may reflect virtually absent FasL function in the Del-Rey
patient and partial function in Patient 86. However, like
the Del-Rey patient, Pt 86 has experienced recurrent epi-
sodes of herpes zoster suggesting that this patient has
altered cellular and humoral immune function as sug-
gested by his depressed immunoglobulin levels.
The identification of Pt 86 and the present studies of the
basis and mechanisms by which his mutation impairs
apoptosis afford new insights into FasL biology. While the
lpr and gld murine mutations in Fas or FasL, respectively
manifest their phenotype in the homozygous state [7,40],
most ALPS patients including Pt 86 carry heterozygous
mutations [3,4]. Because human populations are usually
not inbred, it was important to understand how hetero-
zygous mutations impair cell death effector functions.
Since Fas transduces the death signal as a homotrimeric
complex, we showed that individual mutant Fas proteins,
as seen in nearly all patients with ALPS Type Ia, domi-
nantly inhibit apoptosis mediated by wild type Fas [4].
Now corresponding analyses of mutations in FasL have
been made possible by the discovery of Pt 86.
Molecular modeling predicts that this A530G mutation is
at a surface-exposed residue near the Fas/FasL interface,
suggesting that the mutation directly impairs Fas/FasL
interactions. We showed that the mutant FasL chain asso-
ciates readily with the wild-type chain and thereby domi-
nantly interferes with apoptosis induction by wild-type
FasL. By contrast, the gld mutation likely impairs Fas bind-
ing indirectly through disrupting the structure of the FasL
Cytotoxic effects of patient PBLs on Jurkat cellsFigure 5
Cytotoxic effects of patient PBLs on Jurkat cells. The acti-
vated PBLs from normal controls (open), Pt 86 (FasL R156G, 
black), and father of Pt 86 (shaded) were used as the effector 
cells to mix with Jurkat (target) cells at the E/T ratios shown. 
Means and error bars of % target cell death are shown, data 
represent two independent experiments.
0
20
40
60
80
100
3:1 6:1
E/T ratio
%
ta
rg
et
-c
el
ld
ea
th
Normal
Pt 86
Pt 86FPage 11 of 14
(page number not for citation purposes)
BMC Medical Genetics 2007, 8:41 http://www.biomedcentral.com/1471-2350/8/41trimer. The mutation in Pt 55C is a highly conservative
one in which the methionine normally found at position
86 within the transmembrane domain of FasL in humans
is replaced with another hydrophobic residue, valine,
which is in fact found at this site in mice. Thus, it was not
surprising that the FasL of Pt 55C can associate success-
fully with wild type FasL and does not interfere with the
apoptotic killing mediated by wild type FasL.
Assuming that the wild type and Pt 86 mutant forms of
FasL protein are synthesized equally, have equal stability
(which would be difficult to confirm experimentally), and
participate in trimer formation at random, the trimeric
complexes generated by combinations of these molecules
would include one-eighth of them comprised entirely of
mutant FasL peptides, three quarters with one or two
mutant FasL peptides, and one-eighth with only wild type
FasL. Thus, some residual amount of normal FasL trimers
would be expected and this might explain the residual
apoptosis in PBLs of Pt 86 and his father (Figure 5).
The father of patient 86 carries the same mutation as his
son, and while he is reported to have had significant ade-
nopathy during childhood, he does not currently manifest
Physical association of FLAG-tagged mutant FasL with HA-tagged wild type FasLFigure 6
Physical association of FLAG-tagged mutant FasL with HA-tagged wild type FasL. (a) Lanes 1, 2 and 3 contain extracts from 
cells transfected with the FLAG-tagged mutant FasL constructs (A320G, A530G and hgld) alone and lanes 4, 5 and 6 are from 
cells co-transfected with one of FLAG-tagged mutant FasL constructs and the HA-tagged wild type FasL construct. An anti-HA 
antibody was used for the immunoprecipitation and an anti-FLAG antibody was used for Western blot analysis. The double 
bands appearing at about 40 kD represent two FasL isoforms with different glycosylation patterns. (b) Western blot analysis of 
transfected cell lysates. The FLAG-tagged FasL with the mutations (lanes 1–3) were expressed in 293T cells, and FasL expres-
sion was detected by Western blotting with an anti-FLAG antibody.
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BMC Medical Genetics 2007, 8:41 http://www.biomedcentral.com/1471-2350/8/41sufficient clinical features for the diagnosis of ALPS to be
made. Variable expressivity of heterozygous mutations
was confirmed early in our studies of ALPS Type Ia fami-
lies with Fas mutations [4]. The present data reveal paral-
lel findings in ALPS Type Ib families with FasL mutations.
Further investigations into other gene contributions may
reveal the molecular basis for variable penetrance in ALPS.
Conclusion
This report shows that an amino acid substitution in FasL
generates a mutant protein that binds to and dominantly
interferes with the function of the normal FasL thus
explaining how a heterozygous FasL gene mutation causes
ALPS Type Ib.
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